Northway Biotech
16.11.2023 14:21:41 CET | ACCESS Newswire | Press release
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ondas to Launch LADOS, a Layered Autonomous Defense Operational C2 Layer, at Eurosatory 202610.6.2026 14:30:00 CEST | Press release
LADOS connects Ondas' systems, including sensors, effectors, autonomous platforms, and command units, into one immediate operational core for integrated missions and serves as a critical systems-of-systems command-and-control layer LADOS is part of Ondas' multi-domain software architecture that includes SkyWeaver, a Palantir-powered Agentic AI layer for Multi-Domain Mission Autonomy and long-range ISR-to-assault applications The system will be officially launched at Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions WEST PALM BEACH, FL / ACCESS Newswire / June 10, 2026 / Ondas Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous drone and advanced defense technologies, today announced that it will officially launch LADOS - a Layered Autonomous Defense Operational C2 System, during Eurosatory 2026 in Paris, France, one of the world's premier international defense and security exhibitions. LADOS serves as
Agassi Sports Entertainment Signs Tennis Coaching Icon Darren Cahill to Expand Global Coaching, Content and Technology Initiatives10.6.2026 14:30:00 CEST | Press release
Former coach to Andre Agassi joins ASE to support the Company's Agassi Intelligence platform, premium content initiatives and global growth strategy LAS VEGAS, NV / ACCESS Newswire / June 10, 2026 / Agassi Sports Entertainment Corp. (OTCID:AASP) ("ASE" or the "Company"), a sports, media, and technology platform focused on the global racket sports ecosystem and built around the iconic brands of Andre Agassi and Stefanie Graf, today announced that it has entered into a name and likeness license agreement with renowned tennis coach Darren Cahill. As a member of the team, Cahill will collaborate with ASE across a range of strategic initiatives, including the Company's previously announced Agassi Intelligence technology platform being developed in partnership with IBM, original content creation, media opportunities and other global growth initiatives designed to expand access to world-class coaching and deepen fan engagement across racket sports. Cahill, a former professional player and one
Leggett & Platt Automotive Launches New Brand Identity: Leggett Dynamics10.6.2026 12:50:00 CEST | Press release
ACCELERATES INNOVATION & GROWTH IN COMFORT, MOTION & SOFTWARE INTEGRATED SYSTEMS DETROIT, MI / ACCESS Newswire / June 10, 2026 / Leggett & Platt Automotive today announced the launch of its new brand identity, "Leggett Dynamics", and tagline "eMotion & Comfort for everyone, everywhere, every day" signaling a strategic shift to accelerate innovation and growth in comfort and motion systems for automotive, adjacent and diversified markets. Megatrend & Consumer Shifts "Leggett Dynamics creates experiences where comfort and motion feel effortless, intelligent, personalized and instinctive across all aspects of life. This positions us well in the market in terms of megatrends as well as anticipating and proactively innovating for future expectations," said Marinela Cirstea, President of Leggett Dynamics. According to Cirstea, comfort and motion are at the epicenter of converging megatrends and shifting consumers' priorities toward personalized experiences, health and wellness, plus instant
Camino Intercepts High-Grade Copper With 76.2m at 0.88% Cu Including 16.25m at 2.67% Cu and 6.82g/t Ag at Costa de Cobre in Peru; All Five Reported Drill Holes Intersect Strong Copper Mineralization10.6.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / June 10, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the exploration results from Phase 2 of the recent drilling campaign at its Costa de Cobre project ("Costa de Cobre" or the "Project" (formerly known as "Los Chapitos"(1)) in Peru. Camino completed five drill holes along the Diva trend corridor, where drilling activities focused on the Adriana target with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. The maximum drill hole depth was 260 metres and all five drill holes intercepted strong copper mineralization and spanned a strike length of approximately 400 metres. Key highlights of recent Costa de Cobre drill holes: Adriana: DCH-131: 69.8 m @ 0.47% Cu & 4.17 g/t Ag, including 32.0 m @ 0.75% Cu & 6.50 g/t Ag, and 9.75m @ 1.25% Cu & 6.46 g/t Ag, including 3.90 m @ 2.99% Cu & 15.63 g/t Ag Adrian
From Retrofit to AI: Akkodis Strengthens Digital Innovation Through Industrial Aerospace Applications at ILA Berlin 202610.6.2026 06:45:00 CEST | Press release
At ILA Berlin 2026, Akkodis will showcase concrete applications in digital engineering, AI-driven analytics and industrial execution across the entire aerospace lifecycle - from initial digital design to real-world aerospace applications. BERLIN, DE / ACCESS Newswire / June 10, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, demonstrates how digital development, artificial intelligence and industrial execution come together to bring new solutions into aerospace applications faster at ILA Berlin 2026. Image: Akkodis at ILA Berlin 2026. Source: AkkodisIn 2026, the aerospace and defense sector is being shaped by strong growth and sustained long-term demand, supported by continued investment in innovation and next-generation technologies. At the same time, increasing pressures on efficiency, availability and sustainability are driving a shift toward solutions that can be rapidly integrated and scaled. At the center of Akkodis' presence is a n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom